Cost of Menopause in the United States: What It Costs the Country, and What It Costs You

This page is independent editorial research. It is not medically reviewed by a clinician and is not medical advice. See our medical review policy.

The cost of menopause in the United States is not one audited number. The clearest current cross-study estimate is about $30.2 billion a year: RAND's $5.4 billion productivity model plus roughly $24.8 billion in medical spending. That combination is The HRT Index's calculation, not an official national total, and it leaves major costs uncounted.^[1][2]

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Best for	Not for you if
You want the national number and what it actually measures	You only want current medication or provider prices → How much online HRT costs in 2026
You're working out what menopause may be costing you	You want a ranked provider comparison → Best online HRT providers for menopause
You're citing the figure for work, policy, journalism, or benefits planning	You need personal medical advice or urgent symptom evaluation
You want state and industry data without the usual double-counting	You already know your treatment is not working → HRT dose too low: causes to check

Here's the part nobody tells you. There is no single audited national total. The headline figures were built by different teams, in different years, measuring different things. Some can be combined carefully. Others count the same loss twice.

We opened the source data and did the math ourselves. What we found changes how you should read every one of these figures—including the one about your own state.

Before you go further: is the number really the decision?

Answer: No. The national estimate tells you the size of the problem; it cannot tell you whether online care is right for you, which medication route fits, what your plan covers, or what a consult will cost. Those decisions depend on your symptoms, history, uterus status, state, insurance, and treatment preference.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

What did The HRT Index actually verify for this page?

Answer: We reconstructed RAND's national productivity model from its published inputs, derived a per-worker figure for every state and Washington, D.C., checked RAND's state and industry tables against its published national total, re-read current provider pricing, and verified enacted state laws against legislative or statutory text.

We did this ourselves in August 2026:

• Rebuilt RAND's model from its stated assumptions: 212 workdays; 10.8% missing an average of three days; 5.6% cutting hours across five days, modeled as half-days; and 0.3% laid off for an assumed 24.1 weeks.^[1]
• Divided every RAND state total by RAND's corresponding workforce count to produce the per-worker state figures below. RAND does not publish that derived column.
• Checked RAND's source-table arithmetic. The 51 state rows sum to $5,411,105,173, which is $12,385 above the published national total of $5,411,092,788. The 20 industry rows sum to $5,411,105,133, or $12,345 above the national total. Both population tables are one person below the national count. We preserve the published national figure and the published rows instead of quietly changing one.
• Re-read Midi Health's published self-pay prices, commercial-insurance language, Medicare status, and Medicaid/Medi-Cal restrictions on August 10, 2026.^[16]
• Re-checked Louisiana, Illinois, Oregon, New Jersey, Virginia, Washington, and Rhode Island against official legislative or statutory sources.^{[10][11][12][13][14][15]}

What we refuse to do: add numbers that measure the same thing twice, turn a commissioned association into proof of causation, assign the entire cost of a disease to menopause, or publish a personal price range that has no defensible denominator.

---

How much does the cost of menopause in the United States add up to each year?

Answer: The best current cross-study estimate is about $30.2 billion annually: RAND's $5.411 billion model of lost days, reduced hours, and layoffs, plus roughly $24.8 billion in medical spending restated by RAND from Mayo's framework. No single study published that combined total, so call it a transparent estimate—not an official U.S. number.^[1][2]

You've probably seen four or five different numbers. They're real. They just do not mean the same thing.

The U.S. Menopause Cost Ledger

Figure	What it measures	Source and data frame	Who is counted	What it leaves out	Can it be added to another figure?
$1.8B/yr	Wage value of missed workdays	Mayo Clinic study published 2023; survey conducted 2021; national estimate used 2020 wage/workforce inputs	Employed women ages 45–60	Reduced hours, layoffs, resignations, early retirement, presenteeism, medical spending	Do not add it to $5.4B or $26.6B. RAND updates and expands this productivity framework; $26.6B already contains it
$5.411B/yr	Missed days + modeled reduced hours + modeled layoffs	RAND, published 2025, using 2023 ACS workforce and wage data plus 2025 unemployment-duration input	Full- and part-time employed women ages 45–60	Medical spending, presenteeism, resignations, early retirement, missed promotions, unpaid work, women under 45	It can be combined cautiously with a non-overlapping medical-spending estimate
~$24.8B/yr	Medical spending associated with menopause symptoms	Restated by RAND from Mayo's framework using 2020 Census population and inflation-adjusted per-woman estimates	U.S. women ages 45–60	Not the same as a woman's out-of-pocket bill; does not capture every downstream condition	Do not add it to Mayo's full $26.6B, because it is already inside that figure
$26.6B/yr	Mayo's $1.8B missed-work estimate + roughly $24.8B medical spending	Mayo Clinic, 2023	As above	Reduced hours, layoffs, early retirement, presenteeism, unpaid work	Do not add it to $1.8B. If using RAND's newer productivity model, replace—not stack—the $1.8B component
>$13B/yr	Consumer-reported spending on menopause symptom management	AARP survey, fielded September 2023 and published 2024	U.S. women 35+ with at least one symptom	Lost income and employer costs	Likely overlaps medical and consumer-spending figures; do not stack it into a national total
$1,243 vs $848 PMPM	Average allowed medical + pharmacy cost for a claims-defined menopause group versus all female medical utilizers ages 45–54	Milliman, 2021 commercial claims; commissioned by Gennev	Commercially insured women ages 45–54 who met the report's claims definition	It is not a causal estimate or a national total	No. It is a per-member claims comparison
$248/person/yr	Historical direct care cost associated with menopausal symptoms	Assaf et al., using 2010–2012 MEPS data	Women ages 45–65 without hysterectomy	Prescription costs; current prices and care patterns	Historical context only
$57B → $95B	Total societal cost of osteoporotic fractures, 2018 → 2040	Lewiecki et al. modeling	U.S. fracture burden, heavily Medicare-weighted	The menopause-attributable share is not isolated	Never add the whole figure to a menopause total

Terms, defined once: Productivity loss is the wage value assigned to work that did not happen—missed days, reduced hours, or a modeled job loss. Direct medical spending is spending paid through clinicians, facilities, pharmacies, and insurance. PMPM means “per member per month.” Presenteeism means being at work but working below normal capacity.

So what's the honest headline?

If somebody needs one sentence, this is the one we'd stand behind:

Menopause symptoms cost the United States about $30.2 billion a year in the clearest current cross-study estimate—$5.411 billion in modeled productivity loss plus roughly $24.8 billion in medical spending—but no research team has published that combination as an official national total.

That sentence is less tidy than “menopause costs America $30 billion.” It is also true.

The components use different base years and different methods. RAND's productivity model uses 2023 workforce data and a 2025 unemployment-duration assumption; the medical figure uses a 2020 population base and earlier per-woman cost work. Treat $30.2 billion as a magnitude, not a decimal-precise invoice.

We're the ones combining it, and we're telling you so.

---

Why do trustworthy sources say $1.8 billion, $5.4 billion, and $26.6 billion?

Answer: They measure overlapping and non-overlapping pieces. Mayo's $1.8 billion covers missed workdays. RAND's $5.4 billion updates that model and adds reduced hours and layoffs. Mayo's $26.6 billion already combines the $1.8 billion with roughly $24.8 billion in medical spending. Adding all three would count the same missed-work loss more than once.^[1][2]

Three things keep going wrong.

One: the $1.8 billion gets credited to the wrong study. It came from the Mayo Clinic workplace study led by Dr. Stephanie Faubion. RAND cited and expanded that framework. RAND did not originate the $1.8 billion estimate.^[1][2]

Two: $26.6 billion gets described as lost productivity. It isn't. Mayo described $1.8 billion in lost work time and $26.6 billion when medical expenses are added. Roughly $24.8 billion of that combined figure is medical spending.^[2]

Three—and this is the big one—people stack $5.4 billion on top of $26.6 billion. That leaves the $1.8 billion missed-work component inside the Mayo total while adding RAND's broader replacement productivity estimate on top of it.

The three rules that stop the double-counting

Rule 1 — Never add $1.8 billion to $26.6 billion. The $1.8 billion is already inside the $26.6 billion.

Rule 2 — Never call $26.6 billion a productivity figure. It is mostly medical spending.

Rule 3 — Never add the full cost of osteoporosis, heart disease, depression, urinary infections, or any other condition to a menopause total unless research has isolated the menopause-attributable share. Anything else is arithmetic inflation.

Quote each figure correctly

On RAND's $5.4 billion

✅ Say: “RAND estimated $5.411 billion in annual U.S. productivity losses associated with menopause symptoms, using 2023 workforce data and modeling missed days, reduced hours, and layoffs.”

❌ Don't say: “Menopause costs the U.S. $5.4 billion a year.” That sentence drops medical spending and every unmeasured category.

On Mayo's $26.6 billion

✅ Say: “Mayo Clinic reported a combined $26.6 billion annual framework: $1.8 billion in lost work time plus roughly $24.8 billion in medical expenses.”

❌ Don't say: “Menopause costs employers $26.6 billion in lost productivity.”

On the $225 per-worker figure

✅ Say: “RAND's national model averages to about $225 for each employed woman ages 45–60 when spread across the entire modeled population.”

❌ Don't say: “Menopause costs the average woman $225 a year.” That turns a population-level model into a personal bill.

On the Milliman claims comparison

✅ Say: “In a Gennev-commissioned analysis of 2021 commercial claims, the claims-defined menopause group averaged $1,243 PMPM, compared with $848 for all female medical utilizers ages 45–54.”

❌ Don't say: “Menopause makes women 47% more expensive to insure.” The study is descriptive, the groups differ in care-seeking and claims identification, and the comparison does not prove cause.^[6]

The damaging admission, up front

There is no single audited national total for the cost of menopause in the United States, and the strongest studies do not measure the same slice of the problem.

We could have written a cleaner page by picking one number and running with it. Most pages do. But the reason you found contradictory figures is that contradictory figures genuinely exist, and a page that hides that is not helping you—it is adding another one.

---

How much does menopause cost one woman a year?

Answer: There is no defensible national “average bill” for one woman. RAND's productivity model averages to about $225 per employed woman ages 45–60, but that is a population allocation, not a typical personal loss. Its inputs imply sharply different scenarios: $0 for no measured work disruption, about $743 for five modeled half-days, $891 for three missed days, or about $29,138 for a 24.1-week layoff at RAND's national wage.^[1]

This is the section we'd keep if we could only keep one.

Take RAND's published national total—$5,411,092,788—and divide it by the 24,047,236 employed women ages 45–60 in its national row. You get $225.02 per woman per year.

That number is arithmetically correct. It is also a bad description of an individual woman's experience.

We rebuilt RAND's model. Here's what's inside the $225.

RAND publishes the inputs: 212 workdays a year; 10.8% of women missing an average of three days; 5.6% cutting hours across a median of five days, modeled as half-days; and 0.3% laid off, with an assumed 24.1 weeks of unemployment.^[1]

Modeled source of loss	Population-average days of pay	Share of RAND total	RAND national amount
Missed workdays	0.324	42.7%	About $2.31B
Reduced hours	0.140	18.5%	About $1.00B
Layoffs	0.295	38.8%	About $2.10B
Total	0.759	100%	$5.411B

Our reconstruction reproduces RAND's published split to one decimal place.

Look at the layoff row again

Nearly 39% of the model comes from layoffs reported by 0.3% of the Mayo respondents and then valued using RAND's unemployment-duration assumption.

That fact reframes the $225. It is not a recurring invoice. It is a rare, expensive outcome spread across more than 24 million workers.

Using RAND's national average income of $62,871 and $297 per workday, the model's conditional scenarios look like this:

What happens in the model	Conditional income loss
No measured missed days, reduced hours, or layoff	$0
Three full workdays missed	About $891
Five half-days of work lost	About $743
24.1 weeks unemployed after a layoff	About $29,138

The last row is roughly 129 times the population average.

The honest risk is not that every woman loses $225. The honest finding is that a population-wide average hides a small group carrying a much larger modeled loss.

Build your own cost picture without inventing a number

Do not start with a national average. Write down the costs that actually apply to you:

Your line item	What to enter	Where to verify it
Missed unpaid work	Days or hours × your actual take-home pay rate	Your pay records
Paid leave used	Days or hours, even if income was not lost	Your leave balance; this is time cost, not lost wages
Reduced schedule	Hours cut × your actual hourly value	Payroll or scheduling records
Clinician visits	Your copay, deductible, or confirmed self-pay fee	Insurer and provider before booking
Prescription	Your exact product, dose, quantity, pharmacy, and plan	Formulary and pharmacy quote
Labs or imaging	Only the tests actually ordered	Provider, lab, and insurer
OTC products and supplements	What you actually paid—not what you intended to spend	Receipts or card statement
Travel, childcare, parking	Actual expense	Receipts

That total may be zero. It may be modest. It may be brutal. But at least it will be yours.

Your number isn't the national average. Let's find the right next step.

What menopause costs you depends on your state, your coverage, your symptoms, and which treatment route fits your history.

Find My HRT Path gives you a personalized starting-point plan, the questions to ask before you pay, and a flag when online care is not the right place to begin.

→ Get your personalized action plan

---

Does menopause really cost more in some states?

Answer: RAND's total varies enormously by state, but its model does not estimate that menopause is more severe in one state than another. RAND applies the same work-disruption rates nationally, then changes workforce size and wages. When we divide each state total by its workforce count, every jurisdiction lands at roughly 0.76 days of pay, or 0.36% of average income, per modeled worker.^[1]

California leads RAND's absolute state table at about $688 million. Texas follows at about $433 million. Wyoming is lowest at about $6.5 million.^[1]

Read like a health ranking, that map is easy to misuse. It is a payroll map.

Washington, D.C. has the highest derived amount per worker—about $440—because RAND reports the highest average income in the table. Mississippi is lowest at about $162 because its reported average income is lower. The model does not establish that symptoms are worse in D.C. Wages are different.

Lost income per modeled worker, by state and D.C.

These are The HRT Index's calculations: each RAND state total divided by the corresponding number of employed women ages 45–60. The state totals, headcounts, and wages come from RAND Table 1; the derived columns below do not appear in the report.^[1]

State or jurisdiction	Modeled annual productivity loss per employed woman 45–60	Days of pay	Share of average income
District of Columbia	$440	0.76	0.36%
Massachusetts	$281	0.76	0.36%
Maryland	$280	0.76	0.36%
New Jersey	$268	0.76	0.36%
Washington	$267	0.76	0.36%
Rhode Island	$265	0.76	0.36%
New York	$262	0.76	0.36%
Connecticut	$261	0.76	0.36%
California	$255	0.76	0.36%
Colorado	$253	0.76	0.36%
Virginia	$251	0.76	0.36%
Minnesota	$246	0.76	0.36%
Delaware	$239	0.76	0.36%
New Hampshire	$239	0.76	0.36%
Alaska	$238	0.76	0.36%
Illinois	$229	0.76	0.36%
Pennsylvania	$225	0.76	0.36%
Oregon	$222	0.76	0.36%
Arizona	$217	0.76	0.36%
Vermont	$215	0.76	0.36%
Georgia	$214	0.76	0.36%
North Carolina	$214	0.76	0.36%
Hawaii	$212	0.76	0.36%
Nevada	$212	0.76	0.36%
Wisconsin	$209	0.76	0.36%
Texas	$208	0.76	0.36%
Ohio	$206	0.76	0.36%
Nebraska	$206	0.76	0.36%
North Dakota	$205	0.76	0.36%
Michigan	$204	0.76	0.36%
Florida	$202	0.76	0.36%
Maine	$199	0.76	0.36%
Missouri	$197	0.76	0.36%
Iowa	$196	0.76	0.36%
Kansas	$195	0.76	0.36%
Tennessee	$192	0.76	0.36%
Montana	$192	0.76	0.36%
South Carolina	$191	0.76	0.36%
Indiana	$191	0.76	0.36%
Kentucky	$190	0.76	0.36%
South Dakota	$188	0.76	0.36%
New Mexico	$188	0.76	0.36%
Arkansas	$187	0.76	0.36%
Idaho	$186	0.76	0.36%
Utah	$184	0.76	0.36%
Alabama	$184	0.76	0.36%
West Virginia	$184	0.76	0.36%
Louisiana	$182	0.76	0.36%
Wyoming	$180	0.76	0.36%
Oklahoma	$178	0.76	0.36%
Mississippi	$162	0.76	0.36%

What the state table actually proves

The amount per worker tracks wages. Every row resolves to essentially the same 0.76 days of pay and 0.36% of average income because the model applies the same disruption inputs everywhere.

The money is concentrated. The five largest state totals account for 38.0% of RAND's national figure; the top ten account for 55.5%. That is mainly a workforce-size and wage story.

What really can vary by state: which plans are subject to a menopause-coverage law, whether a plan is state-regulated or self-funded, telehealth licensing, provider availability, and the formulary attached to a specific insurance product. RAND's cost map does not measure those differences.

---

Which industries carry the biggest share of RAND's productivity estimate?

Answer: Health care and social assistance carries the largest modeled amount at about $1.244 billion, followed by educational services at about $798 million and professional, scientific, and technical services at about $595 million. The top five sectors account for 66.4% of RAND's total because of workforce size and wages—not because the study measured industry-specific symptom severity.^[1]

Rank	Industry	Employed women 45–60	Average wage	Modeled annual productivity loss	Share of U.S. total
1	Health Care and Social Assistance	5,516,490	$62,995	$1,243,763,116	23.0%
2	Educational Services	3,756,091	$59,329	$797,576,119	14.7%
3	Professional, Scientific, and Technical Services	1,741,744	$95,472	$595,154,284	11.0%
4	Finance and Insurance	1,554,881	$89,884	$500,206,225	9.2%
5	Manufacturing	1,757,165	$72,426	$455,487,153	8.4%
6	Public Administration	1,351,414	$74,157	$358,680,760	6.6%
7	Retail Trade	2,059,775	$44,963	$331,473,828	6.1%
8	Other Services (except Public Administration)	1,242,646	$34,962	$155,492,267	2.9%
9	Administrative and Support and Waste Management and Remediation Services	939,142	$43,244	$145,355,406	2.7%
10	Transportation and Warehousing	771,748	$50,026	$138,179,330	2.6%

Two details are worth pulling out.

Retail employs the third-largest number of women in this age band but ranks seventh in modeled cost. Lower wages produce a lower dollar value in a wage-based model. That does not mean the human disruption is smaller.

Health care and education together account for 37.7% of the model. These sectors employ large numbers of women in the modeled age band, which is exactly why workplace flexibility, temperature control, schedule control, access to breaks, and ordinary non-discrimination matter.

RAND also projects that the share of working-age women in the menopausal transition age range will rise nationally through 2050, with substantial variation by state.^[1]

---

Are women in menopause actually more expensive to insure?

Answer: A 2021 commercial-claims analysis found $1,243 PMPM for women who met its claims definition of “experiencing menopause,” compared with $848 PMPM for all female medical utilizers ages 45–54—a 47% difference. The analysis was commissioned by Gennev, is descriptive, and does not prove that menopause caused the cost gap.^[6]

This figure gets quoted in employer decks because it sounds cleaner than it is.

Milliman analyzed nationwide commercial claims for calendar year 2021. The report defined its menopause group through diagnosis and treatment patterns in claims. That matters: women whose menopause appears in a claim are already people using the healthcare system.

So the comparison is not “women in menopause versus women who are not.” It is closer to a claims-identified group versus the full medical-utilizer population in the same age band.

The report also found:

• 41% higher professional-service allowed PMPM in the menopause group.
• Roughly double the costs in several behavioral-health categories.
• $1,447 PMPM for the “menopause, other therapy” group versus $1,292 PMPM for the “menopause, HRT” group—a 12% unadjusted difference as the report frames it.^[6]

That last comparison is not proof that hormone therapy lowers healthcare costs. It was not a randomized trial, and treatment groups can differ in health status, diagnoses, contraindications, care-seeking, plan design, geography, and other factors.

And one more flag, stated plainly: Gennev commissioned the report, and Gennev sells menopause care. That does not make Milliman's arithmetic false. It does mean the commercial connection belongs next to the number every time it is cited.

---

How much do women pay out of pocket for menopause care?

Answer: No national source supports one reliable annual out-of-pocket average. AARP estimated more than $13 billion in aggregate annual symptom-management spending, while a 2025 GoodRx survey found 76% of prescription users spent under $50 a month, 19% spent $50–$100, and 5.4% spent more than $100. Those are different measures, and neither becomes a universal personal budget.^[3][4]

Two datasets tell the story from different angles.

What AARP estimated

AARP's September 2023 survey of 1,510 women ages 35+ estimated more than $13 billion a year in aggregate spending to manage menopause symptoms. AARP published a breakdown of more than $10 billion on nonmedical treatments, more than $2.7 billion on hormone therapy, and more than $4.5 million on copays.^[3]

We're going to be pedantic because it matters: those published components do not reconcile cleanly to the $13 billion total, and the copay figure is printed in millions, not billions. We are not silently “correcting” it. Cite the total as AARP's estimate; do not manufacture a repaired breakdown.

What women reported spending per month in the GoodRx survey

Category	Under $50/month	$50–$100/month	Over $100/month
Prescription medications	76%	19%	5.4%
Over-the-counter treatments	84%	14%	Not separately reported in the article's headline breakdown
Supplements	Not reported as the lead band	23%	5%

GoodRx surveyed 1,500 adult women through YouGov in February 2025. The same survey found that 26% said menopause prescriptions were fully covered, 60% paid a copay, and 8% said their prescriptions were not covered.^[4]

The annual cost ledger that does not guess

Cost line	What is verified	What you must confirm
In-network clinician visit	Your plan determines copay, coinsurance, deductible, and network status	Ask insurer and clinic for an estimate before booking
Cash-pay telehealth visit	Use only a currently published provider price; Midi lists $250 initial and $150 continued-care visits as of August 10, 2026	Whether your visit needs follow-up; whether insurance applies
Prescription	GoodRx's 2025 survey shows most respondents who used prescriptions reported under $50/month, but the tail exceeds $100	Exact drug, dose, quantity, pharmacy, deductible, formulary tier, prior authorization, and cash alternative
Labs	No universal price or universal requirement	Which tests are clinically ordered, where they are performed, and how they are billed
Compounded preparation	No defensible universal monthly price; usually cash-pay and not FDA-approved	Pharmacy quote, formulation, quantity, shipping, and whether an FDA-approved option fits first
OTC products	84% of surveyed users reported under $50/month	Actual products and whether they are helping
Supplements	Spending is widely distributed; supplements are not FDA-approved to treat menopause symptoms	Product, recurring charge, interactions, and a review date
Mental-health care	Plan- and provider-specific	Behavioral-health network, limits, deductible, and visit frequency
Bone-density testing	Medicare covers qualifying bone-mass measurements once every 24 months, or more often when medically necessary; other plans vary[21]	Eligibility, network, and facility billing

The three costs women most often miss in advance: a deductible that makes an “in-network” visit expensive, labs billed separately, and recurring spending on products that are not helping.

For product-by-product and provider-by-provider prices, use the page built to keep those moving numbers current: How much online HRT costs in 2026.

---

Why is menopause treatment so expensive?

Answer: The bill is not one thing. It is the interaction of list price, formulary status, prior authorization, deductible, pharmacy, product form, visit cost, and whether a service bundles anything beyond the consult. GoodRx's October 2024 analysis found menopause-medication list prices had risen 58% over ten years, while average out-of-pocket spending was $14.33 per prescription—an average that hid products exceeding $100 per fill.^[5]

The $14 average and the $100 prescription can both be true. They belong to different products, plans, pharmacies, and women.

Prior authorization means the plan requires approval before coverage. Step therapy means the plan requires a different product first. Neither tells you what is medically right for you; both can determine whether the prescription is affordable.

GoodRx's coverage analysis was a dated October 2024 snapshot, not a promise about your 2026 plan. At that time:

2024 GoodRx finding	Practical meaning
Estradiol, estradiol valerate, estradiol/norethindrone, Mimvey, and Jinteli were among the better-covered products in its analysis	Ask whether a covered FDA-approved generic or alternative fits your prescription
Brisdelle and Veozah frequently faced prior authorization or step therapy	Budget for paperwork and ask what documentation the plan requires
Activella had the highest average out-of-pocket cost in the analysis, at over $100 per prescription; Estrace and Prefest were also high	Verify the exact product and whether another covered formulation is clinically appropriate

GoodRx also reported that list prices had been drifting down since around September 2020 as generic competition increased.^[5]

The point is not “generics are always cheap.” The point is never accept a category average as your quote.

---

Does insurance cover menopause treatment?

Answer: Sometimes fully, often partially, and sometimes not at all. In GoodRx's 2025 survey, 26% reported full prescription coverage, 60% paid a copay, and 8% reported no coverage. Coverage depends on the exact FDA-approved product, indication, formulary, deductible, prior authorization, network, and whether the plan is state-regulated or self-funded.^[4]

FDA-approved treatment and compounded preparations are not the same coverage category

FDA-approved prescription products have been reviewed by FDA for safety, effectiveness, and manufacturing quality for their approved uses. Coverage still varies by product and plan.^[7]

Compounded hormone preparations are not FDA-approved. FDA does not review them for safety, effectiveness, or quality before marketing in the same way it reviews approved drugs, and FDA says it does not have evidence that compounded “bioidentical hormones” are safer or more effective than FDA-approved hormone therapy.^[7][8]

Compounding can serve a specific clinical need—for example, when an approved product cannot meet an individual patient's documented requirement—but it is a different regulatory pathway. It is not interchangeable with FDA approval, and this page will not imply otherwise.

What to verify before assuming you are covered

1. Is the clinician in network for your exact plan—not just your carrier?
2. Is the exact prescription on your current formulary?
3. Is coverage restricted by diagnosis, prior authorization, or step therapy?
4. Does your deductible apply before the plan pays?
5. Are labs, imaging, or follow-ups separate charges?
6. Is your employer plan fully insured or self-funded?

Medicare

Medicare Part D coverage is formulary-specific. Every plan has its own drug list, and plans may use prior authorization or other rules. Check the exact drug, strength, and form in your plan rather than assuming “HRT” is one covered item.^[17]

Medicaid and telehealth eligibility

Medicaid rules vary by state and provider. A provider may be legally unable or unwilling to treat Medicaid beneficiaries outside its enrolled-program structure—even on a cash-pay basis.

Midi Health is a concrete example. As of August 10, 2026, Midi states that it is not enrolled with Medicaid or Medi-Cal and cannot treat those beneficiaries even as self-pay patients. It also says it is not covered by Medicare or Medicare-related plans; Medicare beneficiaries may self-pay but cannot submit claims related to Midi visits, medications, or associated services.^[16]

HSA and FSA

IRS guidance allows HSA/FSA reimbursement for many qualified medical expenses, including prescribed medicines and many over-the-counter drugs. Eligibility depends on the expense and account rules; general-wellness spending and many supplements do not become qualified merely because they are menopause-adjacent.^[18]

Coverage is the biggest swing factor in what you'll pay

Whether a route works depends on your plan type, state, medication, and provider model—four things a national article cannot settle from the outside.

Find My HRT Path helps you narrow the provider model before you book and tells you when your situation should start somewhere else.

→ Check which path fits your coverage

---

Which states require insurers to cover menopause treatment?

Answer: As of August 10, 2026, five states have enacted broad menopause-coverage laws: Louisiana, Illinois, Oregon, New Jersey, and Virginia. Louisiana, Illinois, and Oregon are in effect for applicable plans. New Jersey took effect April 9, 2026 for most covered arrangements, but specified individual and small-employer policies apply beginning January 1, 2027. Virginia also begins January 1, 2027. Washington has a separate refill-access law—not a blanket coverage mandate.^{[10][11][12][13][14][15]}

This is the section most likely to change first.

State	What the enacted law does	Effective or applicability date	What it does not prove
Louisiana	Requires health insurance issuers to cover medically necessary menopause and perimenopause care; bars prior authorization and step therapy for medication prescribed for hormone replacement therapy; includes Medicaid provisions	August 1, 2024	It does not mean every product is free, every plan is state-regulated, or every requested treatment is medically necessary under the plan
Illinois	Requires specified group, individual, and managed-care coverage of medically necessary hormonal and non-hormonal therapy for menopause symptoms in FDA-approved forms; Medicaid language is narrower and addresses medically necessary hormone therapy for menopause induced by hysterectomy	January 1, 2026	It does not support the draft's claim that every Illinois Medicaid menopause treatment has the same broad mandate
Oregon	Requires specified health benefit plans and public employee/educator plans to cover treatment of perimenopause, menopause, and postmenopause; the enacted text ties covered drug treatment to FDA-approved products	Plans/contracts issued, renewed, or extended on or after January 1, 2026	“Covered” does not automatically mean zero cost-sharing or no utilization management
New Jersey	The Menopause Coverage Act requires medically necessary perimenopause and menopause treatment across specified state-regulated coverage arrangements, including broad categories of hormonal, non-hormonal, behavioral, pelvic-floor, bone-health, preventive, education, and counseling services	April 9, 2026 for most covered arrangements; January 1, 2027 for specified individual and small-employer policies identified in the act	It does not make every treatment appropriate for every patient or erase formulary/network rules outside the statute
Virginia	Requires specified insurers, subscription contracts, and HMOs to cover medically necessary menopause and perimenopause treatment and care	Policies/plans delivered, reissued, extended, changed, or premium-adjusted on or after January 1, 2027	It was enacted in 2026 but was not yet in force on this page's verification date
Washington	If a plan already covers FDA-approved prescription hormone therapy, it must generally reimburse a 12-month refill obtained at once when storage and prescribing rules allow; controlled substances receive the maximum refill allowed by law	Plans issued or renewed on or after January 1, 2026	This is not a broad menopause-coverage mandate. It changes refill access for already-covered therapy
Rhode Island	Adds menopause and related conditions to state fair-employment accommodation protections	June 24, 2025	This is workplace protection, not insurance coverage

The self-funded-plan trap

State insurance mandates generally regulate insurance, not every employer health plan. A self-funded private employer plan is commonly governed by ERISA and may not be subject to the same state benefit mandate. Ask HR or the plan administrator one sentence: “Is this plan fully insured or self-funded?”^[19]

A state law can improve access and still not reach your plan. That is not a footnote. It is the difference between believing you have a benefit and actually having one.

---

What's missing from every published menopause-cost number?

Answer: Every major U.S. estimate omits important costs. RAND excludes presenteeism, resignations, early retirement, missed promotions, moves to lower-paying work, unpaid labor, and women under 45. It also cannot directly measure how costs differ by race, ethnicity, or income. That makes $5.4 billion a bounded model, not the full economic burden.^[1]

Here's what nobody has counted cleanly.

Career damage that is not a layoff. RAND excludes early retirement, missed promotions, resignations, and moves to lower-paying or less demanding roles.^[1]

Presenteeism. Being at work while symptoms reduce capacity is named as an omitted category. Nobody on this page has a defensible U.S. dollar total for it.^[1]

Unpaid work. Caregiving, household labor, and other unpaid contributions are not valued in the national model.^[1]

Younger women. RAND's model starts at 45. It explicitly notes that women ages 35–45 with perimenopausal symptoms are omitted.^[1]

Unequal burden. RAND could not disaggregate its cost estimate by race, ethnicity, or socioeconomic status. It notes evidence of greater symptom burden among Black and Hispanic women and women with fewer economic resources, but it does not convert those differences into a subgroup cost total.^[1]

The bone question—handled carefully

Published U.S. modeling estimated total societal costs associated with osteoporotic fractures at about $57 billion in 2018, rising to more than $95 billion by 2040. That includes more than direct medical spending.^[9]

Now the discipline: we are not adding it to the menopause total. Some FDA-approved menopausal hormone therapy products have an indication related to prevention of postmenopausal osteoporosis, but no source here isolates the share of national fracture cost attributable to menopause in a way that can be stacked into $30.2 billion.^[7]

The true burden may be larger than the measured number. That is a defensible conclusion. Assigning the whole cost of fractures, heart disease, or depression to menopause is not.

---

Can treatment or workplace support reduce the economic cost?

Answer: Better symptom control and workplace accommodation may reduce disruption, but the national dollar savings have not been established by a randomized U.S. economic trial. The available evidence supports an association between symptom severity and adverse work outcomes; it does not let a provider, employer, or benefits vendor promise a specific return on investment.^[1][2]

We want to be straight with you, because this is where pages on this topic often stop being trustworthy.

What the evidence supports:

• In Mayo's cross-sectional study, greater symptom severity was associated with higher odds of adverse work outcomes.^[2]
• In the GoodRx survey, 21% reported delaying or skipping menopause-related care because of cost; 12% said they cut back on other essentials; among respondents who stopped medications, hormone therapy, or supplements, 10% cited cost.^[4]
• RAND identifies practical workplace approaches such as flexibility, ergonomic adjustments, support, and non-discrimination as policy directions—not as proven dollar-saving guarantees.^[1]

What the evidence does not support:

• A claim that treating menopause will save the U.S. economy a specific number.
• A claim that one telehealth provider, drug, or employer benefit will produce a guaranteed ROI.
• A causal claim that hormone therapy reduces healthcare spending by 11% or 12% based on the Milliman comparison.

The gap between “cost blocks access to care” and “care pays for itself” is a gap in the evidence. We are not going to fill it with sales copy.

---

Is online menopause care the cheapest way to get hormone therapy?

Answer: Not automatically. An in-network primary-care or gynecology visit plus a covered FDA-approved generic may cost less than cash-pay telehealth. Online care earns its fee when access, appointment speed, or ongoing menopause-focused management is the problem—not because the prescription itself becomes inherently cheaper online.

One honest limitation before anyone sells you anything

Online menopause care can cost more than using a clinician you already have in network.

If your own clinician will assess your symptoms, discuss appropriate FDA-approved and non-hormonal options, prescribe when appropriate, and revisit the plan when it is not working, compare that route first. You may spend less.

But a cheap route that you cannot access, cannot schedule, or cannot get managed is not a functioning route.

What you pay a menopause-focused telehealth service for is the clinical visit and access model—not a magical discount on medication.

One provider example, with the commercial facts separated from the judgment

This page is insurance-sensitive, so a provider that publishes visit fees and works with commercial plans is more relevant here than a compounded-primary cash program.

Midi Health fact	Provider-stated information verified August 10, 2026	What you still need to verify
Initial self-pay visit	$250	Whether your situation needs follow-up and whether another local route costs less
Continued-care visit	$150	Frequency of follow-up for your care plan
Commercial insurance	Midi says it is in network with most PPO plans; coverage varies by plan	Exact network status, deductible, copay, and coinsurance for your plan and state
Medicare	Not covered by Medicare or Medicare-related plans; Medicare beneficiaries may self-pay but may not submit related claims	Your medication coverage through your own Part D plan is a separate question
Medicaid/Medi-Cal	Midi says it cannot treat Medicaid or Medi-Cal beneficiaries, even as self-pay patients	A Medicaid-enrolled local or state-authorized route
Medication model	Midi publicly describes use of FDA-approved hormonal and non-hormonal prescriptions when clinically appropriate	The exact prescription, contraindications, pharmacy cost, and formulary
Labs	Midi says it can direct patients to outside testing and generally uses Labcorp for bloodwork	Whether any test is needed, where it is performed, and how it is billed

Those are provider-stated commercial facts, not a declaration that Midi is right for every woman.^[16]

We deliberately do not place a compounded-primary provider at the center of an insurance and formulary section. Compounded preparations are generally cash-pay, are not FDA-approved, and should not be blurred with FDA-approved medication to create a better affiliate pitch.

Does this sound like your situation—access and follow-up are the problem, not simply the prescription price?

→ Compare insurance-friendly online HRT provider models

Still unsure which model fits? Find My HRT Path starts with your situation rather than a provider.

The HRT Index may earn a commission if you start care through some links on this site. That does not change the criteria, source labels, or negative facts we publish. See our affiliate disclosure.

---

How can you pay less for menopause care?

Answer: The highest-value moves are to verify the exact formulary before the visit, compare the insurance price with the pharmacy's cash price, use an in-network clinician when that route works, ask whether labs and follow-ups are separate, use eligible HSA/FSA funds, and appeal denials with the documentation your plan requires.

In the order we'd actually do them:

1. Get the formulary answer before the appointment

Call the number on your insurance card or use the plan portal. Ask about the exact drug, form, strength, and quantity. “Do you cover estradiol?” is too vague when oral tablets, patches, gels, sprays, creams, inserts, and rings can land on different tiers.

2. Ask whether a covered FDA-approved alternative fits

Do not change the prescription yourself. Ask the prescriber whether a covered generic, different delivery route, or different FDA-approved product would meet the same clinical goal.

3. Compare the copay with the cash price

A discount-card or pharmacy cash quote can be lower than an insurance copay for some generics. It can also be higher. Compare the same strength and quantity, and understand that a cash purchase may not count toward your deductible or out-of-pocket maximum.

4. Ask the lab question out loud

“Are any labs required for my situation, and if they are, are they included in this price or billed separately?”

No universal “menopause panel” price belongs on this page because the tests, indications, facilities, and billing arrangements vary.

5. Ask how many paid follow-ups the model usually requires

A low first-visit fee means little if the plan expects frequent separately billed follow-ups. Ask what continued care looks like before you pay for the first appointment.

6. Use HSA or FSA funds only for eligible expenses

Prescribed medicines, eligible clinical care, and many OTC drugs may qualify. Keep documentation. General wellness products and supplements do not automatically qualify.^[18]

7. Find out whether the state mandate reaches your plan

Ask whether the plan is fully insured or self-funded. If it is self-funded, the state rule may not apply.^[19]

8. Put a review date on recurring supplement spending

Supplements are not FDA-approved to treat menopause symptoms. Review benefits, side effects, interactions, and ongoing cost with a clinician or pharmacist instead of letting a subscription renew indefinitely.^[7]

9. Appeal a denial using the plan's own rules

Read the denial notice, meet the filing deadline, and submit the evidence the plan requires. U.S. Department of Labor guidance says employer plans must have a claims-and-appeals process, and claimants generally receive at least 180 days to appeal an adverse benefit determination.^[20]

Ask the prescriber's office for the diagnosis, prior treatments, contraindications, and clinical rationale needed for the appeal. Do not assume a denial is final, and do not assume an appeal is guaranteed to succeed.

---

How did The HRT Index produce these numbers?

Answer: Every published figure traces to a named, dated source. Our original work is limited to transparent arithmetic: reconciling RAND's source tables, rebuilding its model from published assumptions, calculating per-worker state figures, and calculating shares. We label commissioned research, provider-stated commercial facts, and The HRT Index's own cross-study estimate separately.

What we calculated

1. $30.2 billion cross-study estimate: $5.411 billion RAND productivity model + roughly $24.8 billion medical-spending figure restated by RAND.
2. $225.02 national per-worker allocation: $5,411,092,788 ÷ 24,047,236.
3. State per-worker figures: each RAND state cost ÷ its corresponding employed-woman count.
4. State concentration: top five and top ten state totals as a share of the national figure.
5. Industry shares: each RAND industry total ÷ the national figure.
6. Model reconstruction: the population-average days and shares attributable to missed days, reduced hours, and layoffs using RAND's stated inputs.

What we did not “fix”

RAND's state and industry rows are each slightly above the national total when summed, and both population tables are one person below the national count. We report those differences. They are tiny, but changing a source row to make the table look cleaner would be worse than the discrepancy.

The HRT Index Verification Standard

The HRT Index Verification Standard is the documented process we use to review provider and pricing claims: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly and the full roster quarterly.

We evaluate providers on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not publish a numeric score because one number would hide the details that determine whether a provider fits a particular woman.

No clinician reviewed this page

This is editorial research about economics, pricing, coverage, and policy. It is not clinical guidance, and no clinician reviewed it. That is stated at the top because pretending otherwise would be worse than saying it plainly.

Update schedule

Element	Re-check cadence	Verification method
State coverage and workplace laws	Monthly	Current statute, chapter law, regulator bulletin, and effective-date language
Provider prices and public-program restrictions	Monthly	Provider pricing, terms, insurance, and legal pages
Commercial formulary claims	Quarterly, with a visible data date	Original analysis methodology and current plan-level verification where relevant
FDA approval and labeling	Quarterly or on FDA action	FDA drug and labeling announcements
National cost research	Quarterly literature scan	Original report or peer-reviewed paper
RAND state/industry calculations	When RAND revises or replaces the report	Re-run the published tables and reconciliation

---

What else do women ask about the cost of menopause?

How much does menopause cost the U.S. economy each year?

The clearest current cross-study estimate is about $30.2 billion: RAND's $5.411 billion productivity model plus roughly $24.8 billion in medical spending. It is The HRT Index's transparent combination, not an official total published by one research team.^[1][2]

Is the official number $26.6 billion or $30.2 billion?

$26.6 billion is Mayo's 2023 combined framework: $1.8 billion in missed work time plus roughly $24.8 billion in medical spending. $30.2 billion replaces Mayo's $1.8 billion productivity component with RAND's broader, newer $5.411 billion model. Do not add the two totals together.^[1][2]

How much does menopause cost the average woman?

No reliable national source provides one personal annual total. RAND's model averages to $225 across every employed woman ages 45–60 in its population, but the model's conditional outcomes range from zero measured work loss to about $29,138 for its layoff scenario. Personal healthcare spending must be calculated from actual visits, products, coverage, and work impact.

Does menopause cost more in California than in another state?

California has RAND's largest absolute total because it has a large workforce in the modeled age band and comparatively high wages. When each state total is divided by its workforce count, every jurisdiction resolves to about 0.76 days of pay and 0.36% of average income. The model does not measure state-level symptom severity.^[1]

Is menopause treatment covered by insurance?

Sometimes fully, often partially, and sometimes not. The exact answer depends on the plan, product, indication, formulary tier, deductible, network, prior authorization, and whether a state mandate applies. In GoodRx's 2025 survey, 26% reported full prescription coverage, 60% paid a copay, and 8% reported no coverage.^[4]

Which states have menopause insurance mandates?

Louisiana, Illinois, Oregon, New Jersey, and Virginia have enacted broad coverage laws. Louisiana, Illinois, and Oregon were in effect for applicable plans by August 10, 2026. New Jersey took effect April 9, 2026 for most covered arrangements, with specified individual and small-employer policies beginning January 1, 2027; Virginia also begins January 1, 2027. Washington's law concerns longer refills for already-covered FDA-approved hormone therapy and is not a blanket menopause-coverage mandate.^{[10][11][12][13][14][15]}

Does Medicare cover menopause hormone therapy?

Medicare Part D plans each maintain their own formulary. Check the exact product, strength, route, and plan rules. A telehealth provider's Medicare participation is separate from whether a Part D plan covers a prescription written elsewhere.^[17]

Can I use an HSA or FSA for menopause treatment?

Many qualified medical expenses can be paid or reimbursed, including prescribed medicines, eligible clinical care, and many OTC drugs. Supplements and general-wellness purchases do not automatically qualify. Keep receipts and follow your account administrator's rules.^[18]

Are compounded hormones the same as FDA-approved hormone therapy?

No. Compounded preparations are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing the way it reviews approved products. They can serve a specific clinical need, but they must remain clearly separated from FDA-approved medication in any cost or provider comparison.^[7]

Are compounded hormones cheaper?

There is no reliable universal answer. A compounded preparation is often cash-pay, while an FDA-approved generic may be covered by insurance; the opposite can occur for a high-deductible plan or a poorly covered product. Compare the exact formulation, pharmacy quote, visit model, shipping, and coverage rather than using a made-up monthly range.

Is it cheaper to see my own clinician or use telehealth?

An in-network clinician you already have may be cheaper. Telehealth may be worth the additional visit cost when timely access or ongoing menopause-focused management is the missing piece. Compare total first-year cost, not the first appointment alone.

Does treatment save employers money?

It may reduce symptom-related disruption for some employees, but the research reviewed here does not establish a guaranteed national or employer-specific ROI. Associations between symptom severity, care, and costs should not be turned into a savings promise.^[1][2][6]

Why is there no single official cost of menopause?

No U.S. agency publishes one comprehensive total. The figures come from different surveys, economic models, consumer-spending research, and claims analyses, with different populations and definitions. They were not designed to be stacked without checking for overlap.

---

Still not sure which HRT program is right for you?

You now know what the national numbers measure, what they leave out, and why your own cost can look nothing like the average.

The remaining question is not another statistic. It is what to do next—and that changes with your symptoms, state, insurance, medical history, uterus status, and preferred route.

Take our free matching quiz. It gives you a personalized starting-point plan, shows which provider models fit your coverage and preferences, and flags when your situation should start with an in-person clinician instead of an app.

→ Find My HRT Path

---

Sources

¹ Jennifer A. Heissel, Shannon D. Donofry, Amanda Bonheur, Daniel Shinnick, Julia Rollison, and Wendy M. Troxel. The Economic Impacts of Menopause in the United States. RAND Corporation, RR-A4292-1, September 30, 2025. Used for the $5.411B productivity model, $24.8B restatement, methodology, state and industry tables, and limitations.

² Stephanie S. Faubion et al. “Impact of Menopause Symptoms on Women in the Workplace”. Mayo Clinic Proceedings. 2023;98(6):833–845. DOI: 10.1016/j.mayocp.2023.02.025. Mayo's public summary states $1.8B in lost work time and $26.6B when medical expenses are added.

³ Joanne Sauer et al. The Economic Impact of Menopause: A Survey of Women 35+ and Employers. AARP Research, January 2024; fieldwork September 2023.

⁴ GoodRx Research. “The Cost of Menopause: New Survey Highlights Financial Struggles”. Published April 17, 2025; YouGov survey of 1,500 adult women, February 22–28, 2025.

⁵ GoodRx Research. “Menopause Medication Prices Are Up 58% Over the Last Decade”. Published October 23, 2024. Coverage and price findings are presented as a dated 2024 snapshot.

⁶ Milliman. Healthcare Cost and Utilization for Women in Menopause. June 2023; calendar-year 2021 commercial claims; commissioned by Gennev.

⁷ U.S. Food and Drug Administration. “Menopause”; “Hormone Replacement Therapies Can Help Women With Bothersome Menopausal Symptoms”; and FDA materials on compounded hormone products. FDA distinguishes FDA-approved hormone therapies from compounded products that are not FDA-approved.

⁸ The Menopause Society. 2022 Hormone Therapy Position Statement. Used for the distinction between approved therapies and compounded preparations and for individualized treatment framing.

⁹ E. Michael Lewiecki et al. “Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States”. JBMR Plus. 2019. The $57B and $95B figures are total societal fracture-cost estimates, not a menopause-attributable total.

¹⁰ Louisiana Legislature. Act No. 784 of 2024 and La. R.S. 22:988. Effective August 1, 2024.

¹¹ Illinois General Assembly. Public Act 103-0703. Effective January 1, 2026.

¹² Oregon Legislative Assembly. Enrolled House Bill 3064. Applies to covered plans/contracts issued, renewed, or extended on or after January 1, 2026.

¹³ New Jersey Legislature. P.L.2025, Chapter 200, New Jersey Menopause Coverage Act. Approved January 9, 2026. Effective April 9, 2026 for most covered arrangements; specified policies under P.L.1992, c.161 apply January 1, 2027.

¹⁴ Virginia General Assembly. Va. Code § 38.2-3418.23. Enacted 2026; applies beginning January 1, 2027 as specified in the statute.

¹⁵ Washington State Legislature. RCW 48.43.845, effective for plans issued or renewed on or after January 1, 2026; and Rhode Island Public Law 2025, Chapter 226, effective June 24, 2025.

¹⁶ Midi Health. Pricing & Insurance, How Midi Works, and Assignment and Acknowledgement. Re-read August 10, 2026. All Midi facts are labeled provider-stated.

¹⁷ Medicare.gov. “What do drug plans cover?” and “Drug plan rules”. Accessed August 10, 2026.

¹⁸ Internal Revenue Service. Medical-expense FAQs for nutrition, wellness, and general health and Instructions for Form 8889. Accessed August 10, 2026.

¹⁹ U.S. Department of Labor. ERISA overview and research on self-insured health benefit plans. Accessed August 10, 2026.

²⁰ U.S. Department of Labor, Employee Benefits Security Administration. “Filing a Claim for Your Health Benefits” and Benefit Claims Procedure Regulation FAQs. Accessed August 10, 2026.

²¹ Medicare.gov. “Bone mass measurements”. Medicare Part B covers qualifying measurements once every 24 months, or more often when medically necessary. Accessed August 10, 2026.

Update log: August 10, 2026 — Corrected the state-law count and scopes; added Virginia's enacted 2027 mandate; separated New Jersey's April 9, 2026 effective date from its January 1, 2027 individual/small-employer exception; reclassified Washington as a refill-access law; corrected the Milliman comparator; replaced unsupported personal-cost ranges with a reproducible worksheet; re-verified Midi pricing and public-program restrictions; preserved RAND source-table discrepancies instead of normalizing them.